Hepatitis C Information Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatments here at Hepatitis-Central.com.

Search Site

Over 2,750 Pages of
Hepatitis C Info, Here:
Hep C information
Free Newsletter
Hepatitis C Newsletter
We value your privacy. We will not rent your email to anyone.
HEPATITIS NEWS
The top stories compiled from over 5,500 sources, updated every 15 minutes

Vertex recieves FDA approval for Phase III hepatitis drug
Extract not available.

Hepatitis E death toll hits 114
By Dennis Ojwee FOUR more people have died of Hepatitis E in Kitgum district, increasing the death toll to 114. This is out of a cumulative number of 7,331 people infected with the disease, according to district officials. The chairman of the Hepatitis

Rains to worsen Hepatitis E, says official
Gulu The start of the rainy season may worsen the spread of Hepatitis E, Gulu district disease surveillance officer Michael Cankara has said. The warning comes at a time when the disease has claimed over 106 lives and infected over 6000 in various parts

UPDATES AND COMMENTARY RSS Feed

Silymarin Improves Quality of Life During Hepatitis C Treatment
Although a large-scale study concluded long-term interferon therapy to be ineffectual for Hepatitis C management, it demonstrated improvements in quality of life for participants supplementing with silymarin....

Early Hepatitis C Treatment Increases Success
Currently approved treatment for chronic Hepatitis C is about 50 percent effective. New research from Canada claims that early treatment boosts its effectiveness up to 90 percent....

Popular Blood Thinner May Reduce Liver Scarring for HCV Patients
Successful animal studies have paved the way for a human trial to determine if warfarin prevents liver damage in those with Hepatitis C....

table 3

Neurovisual Impairment: A Frequent Complication of Alpha-Interferon Treatment in Chronic Viral Hepatitis

table  3.   Effect of Interferon Treatment on Neurovisual Parameters of Eyes With Baseline Normal or Abnormal P100 Latencies of Visual Evoked Responses
Baseline P100 Latency
P Value
Normal*

(45 patients, 74 eyes)

 Abnormaldagger

(24 patients, 32 eyes)
A. Before treatment
  P100 latency (ms) 117.1 ± 5.7§§ 136.0 ± 8.1# <.0001
  P100 amplitude (µV) 7.07 ± 0.80# 6.85 ± 0.80# NS
  Electroretinogram (µV) 53.1 ± 5.2# 51.8 ± 7.2# NS
  Visual acuity§ 9.1 ± 1.6## 7.9 ± 2.4# .0035
  Visual sensitivity (db) 25.1 ± 1.0** 24.2 ± 1.5*** .0120
B. End of treatment
  P100 latency (ms) 122.3 ± 10.5§§ 136.2 ± 12.8# <.0001
  P100 amplitude (µV) 8.09 ± 8.22# 6.51 ± 1.30# NS
  Electroretinogram (µV) 53.7 ± 5.4# 52.8 ± 7.5# NS
  Visual acuity,§ 8.9 ± 1.8## 7.5 ± 2.4 .0021
  Visual sensitivity (db) 24.1 ± 1.7** 22.3 ± 3.5*** .0201
Abbreviation: NS, not significant.
* VER <127 ms.
dagger VER 127 ms.
Mean ± SD.
§ Snellen score (in 10ths).
§§ P = .0002 (paired and group comparisons).
#P = NS.
##P = .021 (paired and group comparisons).
** P < .001 (paired and group comparisons).
P = .051 (paired comparisons).
*** P = .032 (paired comparisons).

Return To Article
  Hep C information

Information at this website is for educational purposes only; statements about products and health conditions
have not been evaluated by the U.S. Food & Drug Administration.

©1994-2008 Hepatitis-Central.com
Updated 20 Aug 2008